Epstein-Barr virus peptide-Major Histocompatibility Complex class I (EBV pMHC-I)

The target refers to the complex formed by Major Histocompatibility Complex (MHC) class I molecules and specific peptides derived from Epstein-Barr virus (EBV) latent proteins, specifically EBNA1, LMP1, and LMP2. These complexes are predominantly displayed on the surface of EBV-infected cells, including those in EBV-associated malignancies like nasopharyngeal carcinoma and Hodgkin lymphoma (PMID: 25406330). In the context of immunotherapy, these peptide-MHC (pMHC) complexes act as highly specific markers that allow the immune system to distinguish infected or malignant cells from healthy ones. Therapeutic interventions, such as adoptive T-cell therapies (e.g., Tabelecleucel) and TCR-engineered cells, are designed to recognize these specific viral epitopes to induce targeted cell lysis (Atara Biotherapeutics, 2022). Because these proteins are viral in origin, they provide a window for high-specificity treatment with reduced risk of attacking normal host tissues. However, the effectiveness of such therapies can be limited by viral mechanisms that downregulate MHC expression to evade immune detection (PubMed: 31434705). Furthermore, the HLA restriction of these complexes requires patient-specific matching to ensure the therapeutic T cells can recognize the target (StatPearls, 2023).

Other names

EBV-specific pMHCEBNA1/LMP1/LMP2-MHC complexEBV-associated tumor antigenHLA-restricted EBV epitopesEpstein-Barr virus peptide-HLA complex

Targeting of EBV-infected cells via T-cell receptor (TCR) recognition of viral peptides presented on MHC class I, leading to T-cell mediated cytotoxicity.